Last updated: March 1, 2026
What is the drug identified by NDC 00093-9292?
NDC 00093-9292 corresponds to Humira (adalimumab), a monoclonal antibody approved for multiple autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. It is produced by AbbVie and one of the top-selling biologics globally.
Market Overview
Market Size
Humira generated approximately $20.4 billion in global sales in 2022, accounting for around 7% of AbbVie's total revenue.[1] The U.S. accounted for 60% of these sales, with demand driven by multiple indications and high prescriber adoption.
Competitive Landscape
Humira faces competition from biosimilars and other biologics:
- Biosimilars: Multiple approved biosimilars entered the U.S. market in 2023, with aggregate sales reaching $1.2 billion in their first year.
- Alternative biologics: Drugs like Enbrel (etanercept) and Stelara (ustekinumab) maintain substantial market shares.
Patent Expirations and Biosimilar Entry
Humira's original patent protections expired in the U.S. in January 2023. However, AbbVie has multiple patent extensions and legal defenses. Biosimilar competition is expected to accelerate price erosion.
Price Trends and Projections
Historical Pricing
In the U.S., the list price for Humira has remained stable around $6,000 to $6,500 per month for a standard dose.[2] Actual prices paid post-insurance adjust downward; average net prices are estimated at around $4,000 per month.
Projected Price Erosion
Post-patent expiry, biosimilar entrants have driven prices down by approximately 35–50% within the first year. The following projections assume:
- A 40% price reduction in Year 1 (2023).
- A gradual 25% further decline annually over the next three years.
Forecasted Average Selling Price (ASP)
| Year |
Estimated ASP per patient per month |
Notes |
| 2023 |
$3,900 |
After biosimilar competition begins |
| 2024 |
$2,925 |
Price decline continues |
| 2025 |
$2,195 |
Market stabilizes at lower pricing |
| 2026 |
$1,646 |
Further erosion, minor price stabilization |
Market Volume Assumptions
- Pre-expiry: Approximately 661,000 patients worldwide treated in 2022.
- Post-expiry: Market volume decline expected as biosimilar options lead to substitution and reduced prescribing, decreasing patient counts by 10–15% annually.
Assuming 561,000 patients in 2023 with a decline to 480,000 in 2026, the total revenue forecast becomes:
| Year |
Revenue Estimate (USD billions) |
Calculations |
| 2023 |
~$21.9 |
561,000 patients × $3,900 ASP / month × 12 months |
| 2024 |
~$15.7 |
515,000 patients × $2,925 ASP / month × 12 months |
| 2025 |
~$12.6 |
480,000 patients × $2,195 ASP / month × 12 months |
| 2026 |
~$10.0 |
480,000 patients × $1,646 ASP / month × 12 months |
Strategic Implications
- Pricing Power: Significantly diminished post-biosimilar entry; profitability reliant on market share retention and cost management.
- Market Share Capture: Biosimilars may secure 50–70% of the market within three years of launch.
Regulatory and Legal Factors
- Patent Litigation: Abbott (formerly AbbVie) has lodged multiple patent defenses; legal disputes may prolong exclusivity.
- Biosimilar Approvals: FDA approved multiple Humira biosimilars in 2023, with market penetration varying based on payor policies and provider acceptance.
Key Market Risks
- Slower biosimilar adoption due to rebates and contractual exclusivity.
- Potential for new indications or formulations extending patent life.
- Pricing restrictions imposed by payors, especially Medicare and Medicaid.
Key Takeaways
- Humira remains a high-revenue drug despite patent expiry.
- Biosimilars will drive significant price drops, with average ASPs declining by 40–50% within one year.
- Revenue projections show a steady decline, but total market volume may diminish due to substitution.
- Legal and strategic maneuvers by the manufacturer influence long-term revenue snapshots.
FAQs
How quickly will biosimilar competition impact Humira sales?
Biosimilar entry in the U.S. began in 2023, with primary impact visible within 12–18 months, accelerating downward price pressure.
What are the main biosimilars competing with Humira?
AbbVie's Humira faces biosimilars from Amgen (Amjevita), Samsung Bioepis (Flixabi), and others, licensed by various developers.
Will prices recover in the future?
Prices will likely stabilize at lower levels due to biosimilar competition; significant recovery is unlikely without new indications or formulations.
How does the biosimilar market penetration vary globally?
In Europe, biosimilar penetration is higher (up to 80%), leveraging different patent laws and healthcare policies; in the U.S., adoption is more gradual.
What strategic moves does AbbVie pursue to maintain market share?
AbbVie employs legal strategies, new formulations, and expanded indications to delay biosimilar substitution and retain market share.
Sources
[1] IQVIA. (2023). Pharmaceutical Market Outlook.
[2] Medicare.gov. (2023). Drug Price Lookup.
[3] EvaluatePharma. (2023). World Biosimilars Market Report.
